On July 30, Eli Lilly declined 3.09% in regular trading, trading at $1,159.57/share, with turnover of approximately $827 million.

The decline was driven by broad-based selling across the pharmaceutical sector, compounded by ongoing litigation pressure from competitor Novo Nordisk. Within the Pharmacy sector, Sanofi fell 6.88%, Johnson & Johnson dropped 3.91%, and Pfizer declined 2.33%, reflecting significant sector-wide selling pressure.

On the litigation front, Novo Nordisk recently filed a preliminary injunction motion in the US District Court for the District of New Jersey, seeking to immediately halt Eli Lilly's advertising campaigns for Zepbound and Mounjaro. The complaint alleges Lilly's ads compare its drugs against older, lower-dose versions of Novo's semaglutide products while omitting higher-dose data, constituting false advertising and unfair competition. Eli Lilly has denied the allegations, stating its ads are truthful and transparent, and has vowed to vigorously defend the lawsuit. The GLP-1 obesity drug market remains intensely competitive, with Eli Lilly holding approximately 60% market share.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)